XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders’ Equity (Details) - USD ($)
 1 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Feb. 09, 2021
Sep. 29, 2022
Sep. 28, 2022
Sep. 26, 2022
Mar. 31, 2022
Jan. 27, 2022
Dec. 29, 2021
Jan. 18, 2021
Jun. 30, 2022
Sep. 30, 2022
Dec. 31, 2021
Nov. 30, 2019
Apr. 30, 2013
Stockholders’ Equity (Details) [Line Items]                          
Shares authorized                   505,000,000      
Common stock, shares authorized                   500,000,000 500,000,000    
Preferred stock, shares authorized                   5,000,000 5,000,000    
Preferred stock, par value (in Dollars per share)                   $ 0.0001 $ 0.0001    
Warrants term                 5 years        
Exercise price (in Dollars per share)                 $ 15        
Preferred stock conversion, description                   The Series C Convertible preferred stock and the February Warrants each contain a beneficial ownership limitation that restricts each of the investor’s ability to exercise the February Warrants and convert the Series C Convertible preferred stock such that the number of shares of the Company common stock held by each of them and their affiliates after such conversion or exercise does not exceed 4.99% (or, at the election of the Investor, 9.99%) of the Company’s then issued and outstanding shares of common stock.       
Subsequent financing, percentage                   50.00%      
Liquidity damage, description                   If the Company fails to file the Registration Statement or have it declared effective by the dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of their subscription amount, per month, until such events are satisfied.      
Placement agent warrants, description                   In addition, pursuant to the terms of the offering, the Company issued Bradley Woods & Co, Ltd. and Katalyst Securities LLC warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 57,013 shares of common stock, or 10% of the shares of common stock issuable upon conversion of the Series C Preferred Stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment.      
Public offering shares       1,000,000                  
Public offering price per share (in Dollars per share)       $ 5                  
Purchase of additional shares     150,000 150,000                  
Offering issued, description   the Company closed the Offering and issued the Shares for aggregate net proceeds of $4,940,948, after deducting underwriting discounts and commissions and offering expenses. The Company intends to use the net proceeds from the offering for research and development activities, sales and marketing, general working capital purposes, potential acquisitions of other companies, products or technologies, and to repay certain indebtedness. Concurrently with the closing of the Offering, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and conditions of the Representative’s Warrants.   concurrently with the closing of the Offering as discussed above, the Company also issued warrants to purchase an aggregate of up to 57,500 shares of its common stock to the representative of the Underwriters or its designees, at an exercise price of $6.25 per share (the “Representative’s Warrants”). The Representative’s Warrants are exercisable beginning on March 25, 2023, and expire on September 26, 2027, pursuant to the terms and conditions of the Representative’s Warrants.                  
Expired term             Dec. 26, 2026            
Employment agreement, description           pursuant to an Employment Agreement (see Note 8), an aggregate of 16,000 incentive stock options were issued under the 2020 Plan, to Dr. Kou, exercisable at $10.00 per share and expires on January 31, 2032. The stock options vest as follows: (i) 6,000 stock options upon issuance; (ii) 5,000 vests on October 31, 2022 and; (iii) 5,000 vests on October 31, 2023.              
Deferred compensation balance (in Dollars)                 $ 21,658        
Purchase agreement, description the Company entered into pursuant to securities purchase agreements with certain investors pursuant to which it sold warrants to purchase up to 285,067 shares of the Company’s common stock and 4,276 shares of the Company’s Series C Convertible preferred stock. The February Warrants are exercisable for a period of five years from the date of issuance at an exercise price of $15.00 per share, subject to adjustment. If, after a period of 180 days after the date of issuance of the February Warrants, a registration statement covering the resale of the February Warrant Shares is not effective, the holders may exercise the February Warrants by means of a cashless exercise. In addition, pursuant to the terms of the offering, the Company issued the Placement Agent Warrants to purchase up to an aggregate of 57,013 shares of common stock to its placement agents, or 10% of the shares of common stock issuable upon conversion of the Series C preferred stock and February Warrant Shares sold in the offering. The Placement Agent Warrants are exercisable for a period of five years from the closing date of the offering at an exercise price of $17.50 per share, subject to adjustment (see Series C Convertible Preferred Stock Financing above). Such warrants issued to various investors and to the placement agents were recorded as additional paid in capital with an offsetting debit applied against additional paid in capital, thus these warrants have no further accounting effect within the equity section.                        
Placement Agent Warrants [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Risk free interest rate                   0.50%      
Expected dividend yield                   0.00%      
Expected term                   5 years      
Expected volatility                   169.00%      
Aggregate grant date fair value of placement agent warrants (in Dollars)                   $ 1,106,000      
Warrant [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Warrants term               5 years          
Exercise price (in Dollars per share)               $ 10          
Risk free interest rate               0.46%          
Expected term               5 years          
Expected volatility               169.00%          
Stock-based Compensation (in Dollars)                     $ 83,728    
Granted warrants to purchase shares               5,000          
Grant date price per warrant (in Dollars per share)               $ 16.5          
Warrant value (in Dollars)               $ 83,728          
Stock price (in Dollars per share)               $ 17.5          
Series A Preferred Stock [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Designated shares of preferred stock                         1,000,000
Share issued                   0      
Share outstanding                   0      
Series B Convertible Preferred Stock [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Preferred stock, shares authorized                   2,000 2,000    
Designated shares of preferred stock                       2,000  
Share issued                      
Share outstanding                      
Preferred stock, par value (in Dollars per share)                   $ 0.0001 $ 0.0001    
Series C Convertible Preferred Stock [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Designated shares of preferred stock 4,280                 4,280      
Preferred stock, par value (in Dollars per share)                   $ 0.0001      
Preferred stock, stated value (in Dollars)                   $ 1,000      
Convertible preferred stock, description                   A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company’s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.      
Deemed dividend (in Dollars) $ 1,403,997                        
Series C Conversion Price [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Conversion price per share (in Dollars per share)                   $ 15      
Series C Purchase Agreements [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Sale of aggregate shares 4,276                        
Warrant to purchase shares 285,066                        
Gross proceeds (in Dollars) $ 4,276,000                        
Offering expenses (in Dollars) $ 481,898                        
Series C Preferred Stock [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Preferred stock, shares authorized                   4,280 4,280    
Share issued                   0 227    
Share outstanding                   0 227    
Preferred stock, par value (in Dollars per share)                   $ 0.0001 $ 0.0001    
Convertible preferred stock         227                
Convertible common stock         15,167                
Board Granted [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Exercise price (in Dollars per share)             $ 7.3            
Risk free interest rate             0.75%            
Expected term             2 years            
Expected volatility             0.00%            
Aggregate of incentive stock options             6,849            
Stock option value (in Dollars)             $ 30,224            
Expected volatility             115.00%            
Fair value of unvested stock option             30,224            
Fair value of the unvested stock options (in Dollars)                   $ 22,668      
Issuance of deferred compensation balance (in Dollars)                   $ 7,556      
Omnibus Equity Incentive Plan                          
Stockholders’ Equity (Details) [Line Items]                          
Shares of common stock reserved and avail for issuance               170,000          
Incentive Stock Option [Member]                          
Stockholders’ Equity (Details) [Line Items]                          
Risk free interest rate                   1.18%      
Expected dividend yield                   0.00%      
Expected term                   2 years      
Expected volatility                   117.00%      
Fair value of the unvested stock options (in Dollars)                   $ 94,915      
Stock option                   16,000      
Fair value of stock option (in Dollars)                   $ 94,915      
Stock-based Compensation (in Dollars)                 $ 73,257